PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/DFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME activity, based on a recent live webcast, leading experts examine the vital role of primary care physicians in the management of patients who have or are at risk of DR and DME and offer practical insight on current screening recommendations, risk factor management, and novel treatment options to improve outcomes. Upon completion of this activity, participants should be better able to: Reconcile current guidance offered in evidence-based treatment recommendations regarding screening, diagnosis, and treatment of patients with suspected DR with or without DME, Counsel patients with DR with or without DME about the effects a timely diagnosis and initiation of appropriate treatment options can have on outcomes, Implement strategies that overcome barriers to ensure the timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR, Discuss newer treatment options in a manner that overcomes patient-related barriers and encourages them to seek care from ophthalmologic specialists.

Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the mainstay of treatment; however, the recent FDA approval of the first antifibrotic agent specifically for the treatment of SSc-ILD now offers a new avenue of therapy for these patients. Evidence has shown that a multidisciplinary discussion—particularly the input of rheumatologists—often changes a diagnosis to one of the connective tissue disease–associated ILDs, including SSc-ILD, and consequently, the prognosis and treatment. This PeerView web broadcast underscores the importance of this collaboration and the best practices in the management of SSc-ILD. Our expert panel discusses the latest clinical data on antifibrotic therapy for SSc-ILD, as well as evidence-based treatment and recommendations for monitoring disease progression. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and patterns of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc), Recognize the importance of collaborating with other specialists in the diagnosis and management of SSc-ILD, Summarize the latest clinical data regarding efficacy and safety for the use of antifibrotic therapy for SSc-ILD, Apply best practices to the management of SSc-ILD, including evidence-based treatment and recommendations for monitoring disease progression.

Go online to PeerView.com/EVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, an expert ophthalmologist and expert endocrinologist discuss the importance of diagnosing patients with diabetic retinopathy with or without diabetic macular edema early and how individualizing treatment improves outcomes. After participating in this activity, the learner will demonstrate the ability to: Describe current evidence-based recommendations for screening, diagnosis, and treatment of patients with suspected DR with or without DME, Facilitate timely diagnosis and treatment initiation, as appropriate, for patients with DR with or without DME, Incorporate strategies that overcome barriers to ensure timely and appropriate referral to ophthalmologic specialists who can utilize treatment regimens that have been shown to improve outcomes and/or encourage regression of DR in patients with diabetes.

Go online to PeerView.com/NZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses strategies for accurately diagnosing and treating patients with posterior circulation stroke. After participating in this activity, the learner will demonstrate the ability to: Differentiate the signs and symptoms of acute ischemic posterior circulation stroke from other conditions with which it might be confused, Perform stroke assessments that facilitate more rapid diagnosis of acute ischemic posterior circulation stroke, Compare the therapeutic characteristics of current and emerging thrombolytic agents for acute ischemic stroke.

Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a growing body of evidence now supports the use of EGFR-targeted therapy in early-stage disease, with remarkable efficacy results in the adjuvant setting. Results from ongoing studies of neoadjuvant and adjuvant targeted therapy are eagerly awaited as well. Given that targeted therapy is becoming an increasingly useful tool in early-stage NSCLC, it is essential that thoracic surgeons and other members of the multidisciplinary lung cancer team remain current with the latest clinical trial data and practical implications of incorporating systemic therapy into multimodal management strategies. This web broadcast provides the most important information required to effectively navigate the increasingly complex evidence base of EGFR-targeted therapy, focusing on the nuances of molecular testing and targeted treatment in the context of patient-centered, multidisciplinary management of EGFR-mutant NSCLC. Upon completion of this activity, participants should be better able to: Characterize the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, Describe the latest safety and efficacy data on neoadjuvant/adjuvant EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Discuss evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, and the thoracic surgeon’s role in optimizing sample collection and evaluation, Collaborate with the multidisciplinary team to safely integrate neoadjuvant/adjuvant EGFR-targeted therapies into multimodal treatment plans for eligible patients with early-stage NSCLC in the context of clinical practice or clinical trials, according to recent evidence, precision oncology principles, and patient values and preferences.

Go online to PeerView.com/AGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable genetic disorder that primarily gives rise to nervous system tumors but can also lead to multisystem involvement. Neurofibromas are a key feature of NF1, and approximately 50% of patients will develop plexiform neurofibromas (PNs), which are associated with substantial morbidity and carry the potential to transform into malignant peripheral nerve sheath tumors. Optimal care of children with NF1 and NF1-related plexiform tumors includes awareness of the disease biology and the most recent clinical data on innovative therapies for managing the disease. Recent therapeutic developments for NF1 have been tumor-directed, often leveraging agents developed for the treatment of a variety of cancers. Notably, inhibitors of the MAPK signaling pathway, such as MEK inhibitors, offer rational therapeutic options for patients with NF1. This web broadcast features an expert review of treatment recommendations, current management paradigms, and challenges in the care of NF1 and NF1-associated tumors in children, as well as insight into the expanding landscape of targeted therapies and guidance on effectively incorporating these strategies into patient care. Upon completion of this activity, participants should be better able to: Describe fundamental aspects of NF1 etiology, pathophysiology, and clinical presentation as they relate to pediatric patients, Summarize current recommendations for NF1 diagnosis and treatment of NF1-associated tumors in pediatric patients, Evaluate recent evidence regarding the role of emerging therapies in the treatment of NF1-associated tumors in pediatric patients, including agents that affect the RAS/MAPK pathway, Assess options for patient-centered treatment of PNs and other NF1-associated tumors in pediatric patients.

Go online to PeerView.com/RBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiometabolic health discusses the role and ability of SGLT2 inhibitors to improve renal outcomes in patients with T2DM and/or CKD. Upon completion of this activity, participants should be better able to: Outline the mechanism(s) of action and clinical potential of newer options in glucose-lowering therapy that have been shown to improve renal outcomes in patients with T2DM, Evaluate the clinical efficacy and safety of newer options in glucose-lowering therapy in patients with T2DM and/or CKD, Integrate newer glucose-lowering therapies to improve the management of patients with T2DM and/or CKD based on the latest clinical evidence.

Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.

Go online to PeerView.com/VTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is a debilitating, chronic inflammatory disease that is characterized by demyelination and neurodegeneration of the central nervous system. Efforts to provide effective treatments for individuals with MS have led to FDA approval of many disease-modifying therapies since 2010, including the sphingosine-1-phosphate receptor (S1PR) modulators. Newer-generation S1PR modulators have been developed to preferentially target receptors 1 and 5, with the goal of improving safety profiles, which is expected to make these agents better treatment options for more MS patients. Moreover, the S1PR modulators have demonstrated a range of therapeutic benefits, including effects on gray matter atrophy. In this activity, based on a recent live webcast, our expert faculty offer insights into the role of S1PRs in the pathophysiology of MS and therapeutic benefits of S1PR modulators, including effects on brain atrophy metrics, in patients with MS. Upon completion of this activity, participants will be able to: Review the proposed mechanisms of action for sphingosine-1-phosphate receptor (S1PR) modulators and how they may address the pathophysiological defects associated with multiple sclerosis, Summarize key efficacy, safety, and tolerability data available for established, novel, and investigational S1PR modulators for the treatment of multiple sclerosis, Describe the therapeutic potential of current and emerging S1PR modulators for patients with multiple sclerosis, including impact on whole brain and gray matter atrophy metrics, Apply available evidence on established and novel S1PR modulators when managing patients with multiple sclerosis.

Go online to PeerView.com/JDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert narration is combined with 3D animation, patient video segments, and infographic visuals for an engaging presentation on individualized migraine management, including diagnosis and treatment, the role of 5-HT1F receptor agonists for acute treatment, and consideration of patient perspectives. Upon completion of this activity, participants should be better able to: Identify individuals with migraine, including those who are appropriate candidates for acute treatment, according to current treatment recommendations, Address unmet needs in acute treatment of people with migraine, Evaluate the role of 5-HT1F receptor agonists in meeting individual needs in acute treatment of migraine.